GIP抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P00400(GIP Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00400(GIP Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

Gastric inhibitory polypeptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a 42-amino-acid hormone produced by intestinal K cells in response to nutrient ingestion. Initially identified for its ability to inhibit gastric acid secretion, GIP later emerged as a key incretin hormone that stimulates insulin secretion from pancreatic β-cells in a glucose-dependent manner. Beyond its role in glucose metabolism, GIP influences lipid metabolism, adipocyte function, and bone turnover. GIP exerts effects through the GIP receptor (GIPR), a G protein-coupled receptor expressed in multiple tissues, including pancreas, adipose tissue, and brain.

GIP antibodies are tools developed to study GIP's physiological and pathological roles. Polyclonal or monoclonal antibodies targeting GIP or its receptor are used in immunoassays (e.g., ELISA) to quantify GIP levels, in immunohistochemistry to localize GIP-producing cells, or in functional studies to block GIP/GIPR signaling. Recent interest in GIP antibodies has grown due to their therapeutic potential in metabolic disorders. Antagonists neutralizing GIP activity are being explored for obesity treatment, while agonistic antibodies mimicking GIP action are investigated for diabetes management. Notably, dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) have shown superior efficacy in glycemic control and weight loss, reigniting debates about GIP's context-dependent roles. Research using GIP antibodies continues to clarify its complex involvement in energy homeostasis and tissue-specific effects.